Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8484271 | 0.91 | HTR4 (0.44) | SMN1; SMN2LMNAEGFRALDH1A1L3MBTL1 | |
| SCHEMBL8714816 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAEGFRMAPTALDH1A1 | |
| SCHEMBL13601396 | 0.83 | POLB (0.54) | SMN1; SMN2LMNAALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL7372305 | 0.83 | ALDH1A1 (0.48) | SMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL8555290 | 0.83 | LMNA (0.51) | SMN1; SMN2LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL8957048 | 0.82 | LMNA (0.49) | SMN1; SMN2LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL674463 | 0.82 | LMNA (0.49) | SMN1; SMN2LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL29700358 | 0.82 | LMNA (0.49) | SMN1; SMN2LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL8714085 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAMAPTALDH1A1THRB | |
| Hydrochloric Acid SCHEMBL8141456 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224186-B1 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | MILLENNIUM PHARM INC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1224186-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001030780-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, FGB | SMN1; SMN2 4677/4885LMNA 2449/4885EGFR 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.